Sunovion Pharmaceuticals submitted a new drug application to the FDA this week for its apomorphine sublingual film designed to treat motor fluctuations experienced by people with Parkinson’s disease.
The Marlborough, Mass.-based company is testing the film as a therapy for Parkinson’s patients experiencing “off” episodes – when symptoms that are otherwise controlled by medications resurface. As many as 60% of Parkinson’s patients have these kinds of episodes, according to the company.
Get the full story at our sister site, Drug Delivery Business News.
The post Sunovion seeks FDA nod for sublingual film to treat Parkinson’s disease appeared first on MassDevice.